No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
www.tecan.comNo one on the platform currently holds TECN.SW.
No tracked institution reports a position in TECN.SW as of their last filing.
No one on the platform has traded TECN.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -5.5% | 3.8% | ||||
| Profit Margin % | -12.5% | 6.1% | 9.1% | |||
| Free Cash Flow Margin % | 11.6% | 11.4% | 14.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $885M | +0.4% | $6.36 | $6.13–$6.78 | — | 7 |
| 2027 | $932M | +5.3% | $7.62 | $6.54–$8.50 | — | 7 |
| 2028 | $986M | +5.8% | $9.23 | $7.93–$13.32 | — | 6 |
| 2029 | $1.1B | +6.6% | $10.72 | $10.44–$11.01 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $2.53 | $2.63 | +4.0% |
| 2026-03-16 | $3.39 | $4.26 | +25.7% |
| 2025-08-12 | $2.51 | $2.64 | +5.2% |
| 2025-03-12 | $3.66 | $5.23 | +42.9% |
| 2024-08-13 | $4.45 | $2.86 | -35.7% |
| 2024-03-12 | $5.77 | $6.14 | +6.4% |
| 2023-08-15 | $5.59 | $4.16 | -25.6% |
| 2023-03-14 | $6.38 |
| $4.32 |
| -32.3% |
| +0.00% |
| $1.0B |
| — |
| KURN.SWKuros Biosciences AG | $16.96 | +0.47% | $669M | — |
| MED.SWMedartis Holding AG | $83.00 | +0.85% | $1.0B | — |
Source: Financial Modeling Prep · peers by sector/industry